Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Wall Street Analysts Predict an 119.28% Upside in Alpha Cognition Inc. (ACOG): Here's What You Should Know
Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms
Alpha Cognition Inc. (ACOG) Q3 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates
What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
Alpha Cognition to Participate in Upcoming Investor Events
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript